The decision process is long, complex, labor intensive and vulnerable to human errors
Tissue is the issue – in many cancer types, including lung and brain, tissue availability is a limiting factor for full characterization
Personalize drug matching is an ever-harder challenge as the number of immunotherapy options increase
There are over 80 different sub-types of lymphoma, which are treated according to different protocols with very high costs.
Identifying the correct sub-type is a challenging, time-consuming task, requiring the pathologist to combine information from many (>15) different biomarkers.
Information on the co-localization of markers on the same cells is missing as standard-of-care includes staining multiple slides each with a single marker.
Currently, tissue availability limits the ability to fully diagnose each patient and as a result some do not receive targeted therapy.
Staining multiple (5-15) biomarkers on the same slide, in one step (multiplexing).
Mapping each biomarker using a fast hyperspectral scanner
Visualization and AI-Based Decision Support Tools, enabling the pathologist to quickly see the unique features of each patient’s cancer
This detailed information, un-accessible by the human eye nor by standard RGB cameras, enables us to differentiate between the multiple different markers applied to the slide.
Utilizing Fourier spectroscopy combined with imaging, our technology enables fast, efficient scanning, while keeping the system simple and robust.
We are passionate entrepreneurs, with extensive experience in the medical device and healthcare.
We seek to improve lives by overcoming one the greatest challenges faced by the healthcare system in the 21st century – that of precision medicine, and specifically in cancer treatment.
info@pentaomix.com | 10 Plaut St. Entrance B, 3rd floor, Rehovot, Israel
